The sulphonamides which potentially inhibited hCA I and II can be further developed as a novel interesting clinical candidate for the treatment of retinal/cerebral oedema, ischemic diabetic cardiomyopathy, coronary revascularization, diabetic retinopathy, epilepsy, cancer, altitude sickness, COVID-19, etc. Here, CYP24A1 is linked to diabetic retinopathy.